Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;18(10):607-608.
doi: 10.1038/s41571-021-00544-7.

Adjuvant olaparib - should all patients with breast cancer have genetic testing?

Steven A Narod  1
Affiliations
Comment

Adjuvant olaparib - should all patients with breast cancer have genetic testing?

Steven A Narod. Nat Rev Clin Oncol. 2021 Oct.
No abstract available

PubMed Disclaimer

Comment on

  • Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
    Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C, Geyer CE Jr; OlympiA Clinical Trial Steering Committee and Investigators. Tutt ANJ, et al. N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3. N Engl J Med. 2021. PMID: 34081848 Free PMC article. Clinical Trial.

References

    1. Dorling, L. et al. Breast cancer risk genes - association analysis in more than 113,000 women. N. Engl. J. Med. 384, 428–439 (2021). - DOI
    1. Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017). - DOI
    1. Tutt, A. N. J. et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394–2405 (2021). - DOI
    1. Narod, S. A. et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Res. Treat. Apr. 168, 513–521 (2018). - DOI
    1. Jonasson, J. G. et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br. J. Cancer. 115, 776–783 (2016). - DOI

Publication types

LinkOut - more resources